Cilostazol is a quinolinone derivative first developed as an anti-thrombotic agent, inhibiting ADP-dependent platelet aggregation. This is mediated by selective and specific inhibition of cyclic nucleotide phosphodiesterase 3 (IC50 = 200 nM). Because of its effects on platelets, cilostazol is useful in various conditions, including peripheral artery disease, stroke, and post-stent stenosis. It is metabolized to products which also affect platelet aggregation by cytochrome P450 (CYP) isoforms CYP3A4, CYP3A5, and CYP1B1.
